This study is a prospective clinical study to evaluate the effectiveness of combined useof two nasal protective medical devices (Noseguard and Noseguard Night) in reducingrespiratory infection rates, including COVID-19 and influenza, in real-world conditions.The study will also assess usability, satisfaction, and safety using electronicpatient-reported outcomes (ePRO).
This study is a prospective clinical study conducted in Korea to evaluate the
effectiveness of combined use of two nasal protective medical devices, Noseguard and
Noseguard Night, for preventing respiratory infections.
A total of approximately 2,000 adult participants will be enrolled and followed for 8
weeks. Participants will use Noseguard during daytime activities and Noseguard Night
before sleep.
Data will be collected using electronic patient-reported outcomes (ePRO) at baseline and
at Weeks 2, 4, 6, and 8. The primary endpoint is the incidence of respiratory infections,
including COVID-19 and influenza.
Secondary endpoints include symptom severity, duration of symptoms, usability,
satisfaction, and safety outcomes such as adverse events.
This study aims to generate real-world evidence on the effectiveness and usability of
nasal protective devices for respiratory infection prevention.
Device: Noseguard and Noseguard Night
Nasal spray medical devices used to form a protective barrier on the nasal mucosa to
reduce viral entry.
Inclusion Criteria:
- Adults aged ≥19 years
- Able to provide informed consent
Exclusion Criteria:
- Hypersensitivity to device components
- Current COVID-19 or influenza infection
- Severe nasal disease
- Pregnant or breastfeeding women
Jeonbuk University Hospital
Jeonju, South Korea
Investigator: SoHeui Kim
Contact: 82-10-2994-5887
2210325@daewoong.co.kr
SoHeui Kim
82-10-2994-5887
2210325@daewoong.co.kr
Not Provided